ArticleBMC nephrology2025
Efficacy and safety of hydroxychloroquine in IgA nephropathy with nasopharyngeal or intestinal mucosal and non-mucosal infections.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundHydroxychloroquine (HCQ) had shown efficacy in treating Immunoglobulin A nephropathy (IgAN). There are currently no clinical studies evaluating whether the efficacy and safety of HCQ differ in IgAN with concurrent nasopharyngeal or intestinal mucosal and non-mucosal infections at the time of diagnosis.
methodsThis prospective multicenter cohort study enrolled patients aged > 18 years with biopsy-proven IgAN who had received optimized renin-angiotensin-aldosterone system inhibitor (RAASi) therapy for at least 1 month, 24-hour urinary protein creatinine ratio (UPCR) of 0.75–3.5 g/g and estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m². At the time of IgAN diagnosis, patients were divided into the mucosal infection (MI) group and the non-mucosal infection (NMI) group based on whether they had mucosal infections, both groups of patients were treated with HCQ.
resultsThe study enrolled a total of 369 participants, consisting of 192 MI patients and 177 NMI patients. The mean age of the study participants was 37.58 years, with an average eGFR of 85.27 mL/min/1.73 m² and a baseline 24-hour UPCR of 1.92 g/g. After 12 months, the MI group showed a significant reduction in 24-hour UPCR, decreasing from 1.90 ± 0.76 g/g to 0.77 ± 0.31 g/g, with a mean reduction of 58.6%. In contrast, the NMI group had a more modest decline, from 1.94 ± 0.67 g/g to 1.08 ± 0.44 g/g, averaging a 43.8% reduction. Complete remission rate was achieved in 58.3% (n = 112) of the MI group and 47.5% (n = 84) of the NMI group (HR: 1.56, 95% CI: 1.15–2.13, P = 0.004). The overall remission rate was 66.1% (n = 127) in the MI group and 57.6% (n = 102) in the NMI group (HR: 1.65, 95% CI: 1.23–2.21, P < 0.001). Renal function remained stable, no severe adverse events were reported.
conclusionHCQ combined with optimized RAASi safely and effectively reduced proteinuria in IgAN, with particularly superior efficacy observed in patients with concurrent nasopharyngeal or intestinal MI. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.